$Eton Pharmaceutical (ETON.US)$
Major Patent Win: Eton's Game-Changing Liquid Diabetes Drug Gets 20-Year Protection

$Eton Pharmaceutical (ETON.US)$ Reuters
just
Eton Pharmaceuticals Closes Acquisition of Increlex® (Mecasermin Injection)

$Eton Pharmaceutical (ETON.US)$ Eton Pharmaceuticals Announced The Full Readout From The Clinical Trial Evaluating PKU GOLIKE As A Protein Substitute For Phenylketonuria In Patients During Prolonged Fasting Periods
Benzinga· 5 mins ago1min
The study demonstrated that PKU GOLIKE, administered as the last daily dose and compared to standard amino acid protein substitutes, improved metabolic control by reducing harmful phenylalanine (Phe) levels and increasing beneficial tyrosine (Tyr) levels,...

$Eton Pharmaceutical (ETON.US)$
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
Eton Pharmaceuticals has acquired U.S. rights to Amglidia (glyburide oral suspension) from AMMTeK for treating neonatal diabetes mellitus.
The product, already approved by the European Medicines Agency since 2018, has received Orphan Drug Designation from the FDA. Amglidia is a patented liquid formulation targeting approximately 300 U.S. patients with neonatal dia...

$Eton Pharmaceutical (ETON.US)$ Reuters· 2 mins ago
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

$Eton Pharmaceutical (ETON.US)$ Makin that new 52wk high🤫🥂

$Eton Pharmaceutical (ETON.US)$ Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
1 MINUTE AGO, 6:30 AM EDT
VIA GLOBENEWSWIRE
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions
Acquisition to Bolster Eton's Commercial Pediatric Endocrinology Portfolio! Transaction Financed by Eton's Cash and Expanded Credit Facility

$Eton Pharmaceutical (ETON.US)$ like to see some accumulation at this level

$Eton Pharmaceutical (ETON.US)$ Eton Pharmaceuticals Inc: Prescription Drug User Fee Act (Pdufa) Target Action Date Is February 28, 2025